Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
Símbolo de cotizaciónMGX
Nombre de la empresaMetagenomi Inc
Fecha de salida a bolsaFeb 09, 2024
Director ejecutivoDr. Brian C. Thomas, Ph.D.
Número de empleados202
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 09
Dirección5959 Horton St
CiudadEMERYVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94608
Teléfono15108714880
Sitio Webhttps://metagenomi.co/
Símbolo de cotizaciónMGX
Fecha de salida a bolsaFeb 09, 2024
Director ejecutivoDr. Brian C. Thomas, Ph.D.
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos